Drug comparisons
Erenumab vs Atogepant
Compare Erenumab (Aimovig) injectable mAb vs Atogepant (Qulipta) oral CGRP antagonist for migraine. Differences in route, schedule, and suitability.
No comparison dimensions are available for this page.
Clinical context
This comparison occurs when selecting between injectable monoclonal antibody and oral gepant CGRP therapies for migraine prevention.
Bottom line
Erenumab and Atogepant both target CGRP receptors for migraine prevention but differ in formulation and administration.
All medication comparisons